跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
周 百謙
主治醫師
,
臺北醫學大學附設醫院
成員
,
臺北醫學大學生醫器材研究中心
成員
,
臺北醫學大學胸腔醫學研究中心
成員
,
臺北醫學大學細胞治療與再生醫學研究中心
成員
,
臺北醫學大學神經醫學研究中心
成員
,
臺北醫學大學人工智慧醫療研究中心
副教授
,
胸腔內科
https://orcid.org/0000-0002-9413-9876
電子郵件
171010
h.tmu.edu
tw
,
b7801092
tmu.edu
tw
h-index
682
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2025
每年研究成果
概覽
指紋
網路
專案
(9)
研究成果
(40)
類似的個人檔案
(6)
指紋
查看啟用 Pai-Chien Chou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
17%
Alternative Complement Pathway C3 C5 Convertase
26%
Asthma
38%
Bronchiectasis
17%
Cancer-Related Fatigue
35%
Cardiopulmonary Exercise Test
17%
Chemokine
17%
Chronic Cough
17%
Chronic Obstructive Pulmonary Disease
62%
Ciclesonide
17%
Circulating Tumor Cell
17%
Cystic Fibrosis
17%
Diagnostic Accuracy
17%
Disease
21%
Disease Course
17%
Disease Severity
17%
Drug Megadose
17%
Drug Sensitivity
17%
Emphysema
17%
Epidermal Growth Factor Receptor
17%
Epithelial Cell
17%
Ex Vivo
17%
Exercise
22%
Granulomatosis with Polyangiitis
17%
Hand-Schüller-Christian Disease
17%
Health Care Cost
17%
Heart Rate Variability
35%
Histone Acetylation
17%
Interferon
17%
Interstitial Collagenase
17%
Lung Adenocarcinoma
17%
Medicine
35%
Meta-Analysis
17%
Microsphere
17%
Mucosa
17%
Multiple Organ Dysfunction Syndrome
17%
Negative Pressure Ventilation
17%
Neutrophil
17%
Neutrophil Cytoplasmic Antibody
17%
Nuclear Factor
26%
Nucleic Acid Amplification
17%
Observational Study
17%
Obstructive Sleep Apnea
17%
Pulmonary Rehabilitation
17%
Respiratory Disease
17%
Response Evaluation Criteria in Solid Tumors
17%
Sepsis
17%
Small Cell Lung Cancer
35%
Systematic Review
17%
Tumor Necrosis Factor
21%
Immunology and Microbiology
Agonist
10%
Angiopoietin 1
17%
Asthma
100%
Asthma Exacerbation
17%
Bcl-2
17%
Bone Density
17%
Budesonide
17%
C-Reactive Protein
10%
Candida
17%
Cell Death
17%
Chemokine
18%
Ciclesonide
17%
Circulating Tumor Cell
17%
Complement Factor B
26%
Defensin
17%
Drug Megadose
17%
Drug Sensitivity
17%
Dynamic Hyperinflation
17%
Epidermal Growth Factor
17%
Epigenetics
17%
Exercise
19%
Exhaled Nitric Oxide
15%
Forced Expiratory Volume
12%
Glucocorticoid
17%
Granulomatosis with Polyangiitis
17%
Hemodialysis
17%
Histone Acetylation
17%
Hospital Mortality
17%
Hypoxia Inducible Factor
17%
Hypoxia Inducible Factor 1
17%
Infection Resistance
17%
Inflammatory Cytokine
12%
Interferon Type I
17%
Interleukin 33
17%
Interleukin 6
17%
Limb
10%
Mitogen
13%
Mycobacterium Tuberculosis
17%
Neutrophil
21%
Neutrophil Cytoplasmic Antibody
17%
Neutrophil Granulocyte
20%
Normal Human
24%
Nucleic Acid Amplification
17%
Overall Survival
17%
Oxidative Stress
26%
Promoter Region
14%
Repressor Gene
22%
Respiratory Tract Allergy
17%
Systemic Inflammation
17%
Tumor Necrosis Factor
21%
Pharmacology, Toxicology and Pharmaceutical Science
2,3,7,8-Tetrachlorodibenzodioxin
17%
Airway Obstruction
17%
Alternative Complement Pathway C3 C5 Convertase
37%
Anti-Inflammatory Drug
22%
Antiinflammatory Agent
17%
Aromatic Hydrocarbon Receptor
17%
Asthma
59%
Budesonide
17%
Candidemia
17%
Chronic Cough
17%
Chronic Obstructive Lung Disease
41%
Ciclesonide
17%
Cytokine
17%
Cytoprotective Agent
17%
Cytosol Receptor
17%
Disease
35%
Endothelin 1
17%
Epidemic
17%
Epidermal Growth Factor Receptor
17%
Fluorodeoxyglucose F 18
8%
Glucocorticoid
5%
Glucocorticoid Receptor
17%
Hemodialysis
5%
Histone
17%
Histone Acetyltransferase
9%
Hospital Mortality
17%
Hydrogen Peroxide
7%
Inflammation
11%
Interferon
17%
Isoniazid
17%
Lipocortin 5
17%
Lung Adenocarcinoma
17%
Lung Cancer
8%
Malignant Neoplasm
19%
Methacholine
17%
Mitogen Activated Protein Kinase
17%
Neoplasm
22%
Nuclear Factor
37%
Osteosarcoma
17%
Overall Survival
17%
Oxidizing Agent
17%
Pneumonia
21%
Provocation Test
17%
Respiratory Tract Disease
17%
Sleep Disordered Breathing
35%
Small Cell Lung Cancer
17%
Solid Malignant Neoplasm
17%
Transcription Factor AP 1
17%
Tumor Necrosis Factor
17%
Vascular Remodeling
7%
